23

**North Central London**

**Joint Formulary Committee**

|  |
| --- |
| **Shared Care Guidelines: Attention Deficit Hyperactivity Disorder (Children and Adolescents)** |

**Dear GP**

The information in this shared care guideline has been developed in consultation with Primary Care and it has been agreed that it is suitable for shared care.

Sharing of care assumes communication between the specialist or Consultant, GP and patient. The intention to share care should be explained to the patient by the Consultant when treatment is initiated. It is important that patients are consulted about treatment and are in agreement with it.

Contents

[1. Introduction 2](#_Toc42095036)

[2. Shared Care criteria 3](#_Toc42095037)

[3. Shared care responsibilities 3](#_Toc42095038)

[3.1. Consultant 3](#_Toc42095039)

[3.2. General Practitioner 4](#_Toc42095040)

[3.3. Patient and parent or carer responsibility 5](#_Toc42095041)

[3.4. Clinical Commissioning Group 5](#_Toc42095042)

[4. Indications 6](#_Toc42095043)

[5. Dose and Administration 7](#_Toc42095044)

[6. Adverse effects 8](#_Toc42095045)

[7. Cautions 10](#_Toc42095046)

[8. Clinical Monitoring 10](#_Toc42095047)

[9. Contraindications 11](#_Toc42095048)

[10. Drug Interactions 12](#_Toc42095049)

[11. References 13](#_Toc42095050)

[12. Contact Details 14](#_Toc42095051)

[Appendix 1: Transfer form to GP practice 16](#_Toc42095052)

1. Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is a neuro-developmental condition affecting 1-5% of school age children. Its core symptoms include developmentally inappropriate levels of attention, concentration, hyperactivity, distractibility and impulsivity. It causes problems at home, in school and with peer relationships and may have long term adverse effects on self-confidence, academic performance, vocational success and social development.

It is often co morbid with learning difficulties. Untreated, a proportion goes on to develop conduct disorder. Substance misuse is another frequently co morbid problem.

It can be divided into three presentations (based on symptoms): combined presentation, predominantly inattentive presentation: and predominantly hyperactive/impulsive and MUST:

* Have been present for at least 6 months and be developmentally inappropriate.
* Have clear evidence of impairment in social and / or academic functioning in at least two settings
* Be present (i.e. signs) before the age of 12. The signs must not be accountable for by any other type of mental disorder although they may occur in conjunction with some development disorders.

Diagnosis in children and young people should be made by a child and adolescent psychiatrist or paediatrician. It should be based on a multidisciplinary assessment and include information obtained from the child’s school teachers (with parental consent).

**Methylphenidate** (immediate release and long acting), **Atomoxetine**, **Dexamfetamine** and **Lisdexamfetamine** are used for the treatment of ADHD in children (and will be referred to as **“Children and Adolescent ADHD” drug treatments** hereafter within this document)**.**

The time taken to stabilise patients on an optimal dose of medication usually takes approximately 8 – 12 weeks, though this can sometimes take longer. Once achieved, a shared care arrangement will be requested with the GP. This document will clarify responsibilities between the specialist and general practitioner (GP) for managing the prescribing of Children and Adolescent ADHD drug treatment such as:

* Who will prescribe;
* Who will monitor;
* Any tests required (e.g. blood tests), the exact names/nature of the tests, why they are needed, the frequency of testing, the location in which these will be carried out and action to be taken for any abnormal results
* Which clinician will be responsible for receipt and review of the results;
* Who will communicate any necessary changes in dose to the patient and the GP.

This document should provide sufficient information to enable the GP to make an informed decision regarding the clinical and legal responsibility for prescribing these drugs*.*

1. Shared Care criteria

* If medication is indicated as part of the treatment package, then the medication will be initiated in the specialist clinic. Children and Adolescent ADHD drug treatments may form part of a comprehensive treatment programme that focuses on psychological, behavioural and educational advice and interventions.
* Patients will be stabilised on the “Children and Adolescent ADHD” drug treatments and will have been monitored appropriately at baseline and after initiation of treatment, with no problems identified during this period, prior to referral to the GP for shared care.
* Prescribing responsibility will only be transferred when it is agreed by the Consultant and the General Practitioner (GP) that the patient’s condition is reasonably predictable and the treatment regimen has been specified.
* The specialist clinic will continue to provide prescriptions until there has been a successful transfer of the responsibilities as outlined below.
* The patient will be supplied sufficient quantity for 4 weeks which is to be continued by the GP.
* On discharge from specialist services, advice will be given in a letter to continue with treatment in primary care.

1. Shared care responsibilities
   1. Consultant

* Diagnosis of ADHD and decision to initiate treatment.
* Ensure baseline monitoring of height, weight, blood pressure and pulse have been performed, plus any additional relevant investigations (these must be shared with the GP).
* The Specialist must also refer for a cardiology opinion in specific circumstances (or a paediatric hypertension specialist if blood pressure is consistently above the 95th centile for age/height) prior to medication initiation. A full list of cardiac related scenarios where this is necessary can be found in [NICE Guidance](https://www.nice.org.uk/guidance/ng87/chapter/Recommendations).
* The Consultant may request the GP to arrange the cardiovascular examination prior to medication initiation including an electrocardiogram (ECG) if there is a risk factor for cardiac disease (as described in [NICE Guidance](https://www.nice.org.uk/guidance/ng87/chapter/Recommendations)) and the child and adolescent psychiatrist/paediatrician does not have the facility to request for a cardiologist review.
* Discuss the benefits and adverse effects of treatment with the patient (if appropriate) and/ or parents or carers.
* Provide the patient (as appropriate), parent/ carer, and class teachers with written information about ADHD, its management including, medical management, explaining the effects and side effects of medication. Document this discussion in the patient’s clinical notes.
* Assess the effects of the medication, continued liaison is required with the parents or carer and class teachers.
* Initiate and stabilise medication treatment, or according to local agreements regarding minimum supply durations.
* Prescribe the medication until the dose is stabilised (in terms of maximum effect and minimum/ tolerable adverse effects. Doses should be gradually increased until there is no further clinical improvement in ADHD (that is, symptom reduction, behaviour change, improvements in education and/or relationships) and side effects are tolerable.
* Advise when and how to stop the medication, including when drug holidays are recommended.
* Advise on the duration of continuation of the medication and if appropriate transition to adult services.
* Send a letter to the GP along with shared care criteria requesting shared care for this patient. If applicable, communicate to the GP which brand of long acting methylphenidate is to be prescribed, as the different brands are not interchangeable.
* Provide results of baseline tests and recommend frequency of monitoring to GP. The Consultant must also explain what the recommended tests are, why they are needed and the location in which these tests will be carried out.
* Evaluate adverse drug reactions reported by the GP, child, young person or the carer. Report events to the CSM/MHRA via yellow card system, www.yellowcard.gov.uk.
* Set the review interval and criteria. Regular follow up should take place with a child and adolescent psychiatrist or paediatrician until the child’s is stabilised. Following that, 6- to 12-monthly medication review appointments are offered by the CAMHS service. Specialist ADHD nurse, junior doctors and other staff are closely involved with the monitoring of the patients. In addition to medication review appointments, more frequent appointments for behavioural and family interventions may be offered.
* Undertake any necessary monitoring at clinic appointments: blood pressure, pulse rate, weight and height (on a growth chart and record centiles).
* Maintain good communication with the GP by:
* Sending a letter after each clinic visit notifying the GP of changes in medication regime, adverse effects and results of the patient’s routine monitoring.
* Periodically reviewing the patient’s condition and the need for on-going treatment and communicating promptly with the GP when treatment is changed.
* Where blood tests are taken, results should be communicated to the GP, as well as actions to be taken in case of abnormal results, and advising the GP on when to adjust the dose, stop treatment, or when to consult the specialist.
* Counsel the patient and parent or carer on any dose changes that are made during clinic appointments.
* Inform GP of patients who do not attend clinic appointments with any suitable actions needed.
* Ensure that clear arrangements exist for GPs to obtain advice and support.
* Respond to GP queries, usually within 2 working days.
  1. General Practitioner
* Initial referral letter to Tier 3 CAMHS for assessment of ADHD highlighting relevant history and impairments at home and school.
* Prescribe the Children and Adolescent ADHD drugs at the dose recommended by the specialist. The term “as directed” SHOULD NOT be used when prescribing these medicines.
* Adjust the dose as advised by the Consultant or specialist and counsel patient (and /or parent or carer) on any dose changes.
* Ensure that the patient, parent or carer understands the dosing regimen.
* Ensure the patient, parent or carer understands that they must report any adverse effects to the GP and report non-compliance to the specialist or Consultant, where appropriate.
* Ensure compatibility with concomitant medication.
* Monitor results at recommended frequencies as described under “Clinical Monitoring” in section 8 and inform the Consultant if abnormal.
* Help with the monitoring of disease progression and inform the hospital team of any changes to medication.
* Report to and seek advice from the Consultant or specialist on any aspect of patient care that is of concern and may affect treatment.
* Refer back to the Consultant if the patient’s condition deteriorate.
* Seek advice from the specialist when discontinuing medicines, including short-term discontinuations (i.e. drug holidays).
* Stop treatment on the advice of the Consultant or immediately if an urgent need arises.
* Monitor the patient as per the criteria suggested by the initiating Specialist (e.g. patient’s pulse, blood pressure, height and weight). Also monitor patient’s overall health and well-being.
* Respond to requests to arrange a cardiovascular examination including an electrocardiogram (ECG), if there is a relevant scenario (as per [NICE Guidance](https://www.nice.org.uk/guidance/ng87/chapter/Recommendations)) and the Specialist does not have the facilities to provide this through CAMHS.
* Adjust the dose as advised by the specialist (where applicable) and counsel patient on any dose changes
* Report adverse events to the Consultant or specialist and the MHRA/ CSM via Yellow-card located in BNF or online www.yellowcard.gov.uk.
* Communicate any test results to the Consultant.
* All requests from the patient for repeat prescriptions should be reviewed individually prior to issuing.
  1. Patient and parent or carer responsibility
* Attend review appointments at the GP surgery for clinical monitoring as outlined in the original transfer of prescribing letter by the specialist (e.g. blood pressure, pulse, height and weight).
* Attend review appointments with child and adolescent psychiatrist or paediatrician every 6-12 months or as advised, as continuing prescription will not be possible without regular review.
* Take medicines as prescribed and agreed.
* Report to the specialist or Consultant or GP if there is not a clear understanding of the treatment.
* Inform specialist or Consultant or GP of any other medication being taken concomitantly, including over-the-counter products.
* Report any adverse effects or warning symptoms to GP or specialist/ Consultant.
* Inform hospital and GP of any changes in address or telephone numbers.
  1. Clinical Commissioning Group
* To provide feedback to Trusts via the Shared Care and Fact Sheet group.
* To support GPs to make the decision whether or not to accept clinical responsibility for prescribing.
* To support Trusts in the resolving issues that may arise as a result of shared care.

**SUPPORTING INFORMATION**

For further details refer to the manufacturer’s Summary of Product Characteristics (SPC) (on [www.medicines.org.uk](http://www.medicines.org.uk) or <https://products.mhra.gov.uk/>) and current children’s BNF (<https://bnfc.nice.org.uk/>).

1. Indications

**Methylphenidate** (immediate release and long acting), **Atomoxetine**, and **Dexamfetamine** and **Lisdexamfetamine** are indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children of 5 years and older, in adolescents and in adults as part of a comprehensive treatment programme.

These medications are licensed for use in children from the age of 6 years, and do not have a UK marketing authorisation for ADHD in children aged 5 years or under. However, [NICE Guidance](https://www.nice.org.uk/guidance/ng87/chapter/Recommendations) does support the use of these medicines in this population. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](http://www.gmc-uk.org/guidance/ethical_guidance/14327.asp) for further information.

**Note 1**:

* **Lisdexamfetamine** is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 5 years and over when response to previous methylphenidate treatment is considered clinically inadequate.

**Note 2:**

* **Methylphenidate**, **Dexamfetamine** and **Lisdexamfetamine** are schedule 2 controlled drugs (CD) thus are subject to prescription requirements. Prescriptions must include:
  + Name and address of patient;
  + Form and strength of preparation (e.g. 20mg capsules);
  + The dose (e.g. 20mg three times daily) and total quantity or number of dose units in words AND figures (e.g. 420mg = Four Hundred and Twenty milligrams or Twenty One (21) capsules).
  + Signed by the prescribing clinician (either in indelible ink or advanced electronic signature).

* Prescriptions for schedule 2 CDs are valid for 28 days from the date stated on the prescription and prescriptions are limited to a supply of 30 days treatment; in exceptional circumstances, a prescription can be issued for a longer period, but the reasons for the decision should be recorded on the patient’s notes

**Note 3:**

* NICE guidance recommends Methylphenidate (either short or long acting) as the first line pharmacological treatment for children aged 5 years and over and young people with ADHD.

1. Dose and Administration

Refer to most current BNF for children https://bnfc.nice.org.uk/..

For a full list, see manufacturer’s Summary of Product Characteristics (SPC) (on [www.medicines.org.uk](http://www.medicines.org.uk) or <https://products.mhra.gov.uk/>)..

Please note that the BNF for children supports higher than normal doses of some formulations (e.g. Equasym XL, Medikinet XL, Concerta XL etc.). In these instances, the Specialist must take responsibility of titrating the dose upward and stabilising the patient before considering transfer back to the GP.

|  |  |  |
| --- | --- | --- |
| **Drugs covered by the agreement** | **Brand** | **Dosage** |
| Methylphenidate Immediate Release –  Generic  *Schedule 2 CD* | Ritalin®, Equasym®, Medikinet®. | Initially 5mg once or twice daily, increased if necessary at weekly intervals by 5-10mg daily to a maximum of 60mg daily in divided doses. |
| Methylphenidate Modified Release  *Schedule 2 CD* | a) Equasym® XL  b) Medikinet® XL  c) Concerta® XL (branded-generics also include Xenidate XL, Matoride XL, Delmosart and Xaggitin).  (**Prescribe by Brand** due to differing immediate release and modified release components – see [SPS for more information on the different release profiles](https://www.sps.nhs.uk/wp-content/uploads/2018/04/Methylphenidate-March-2018.pdf)). | a) & b) 10mg once daily (in the morning) increased if needed up to max of 60mg once daily.  c) 18mg once daily (in the morning), increased if needed in weekly steps of 18mg according to response, up to a maximum of 54mg once daily. |
| Dexamfetamine Sulphate  *Schedule 2 CD* | Generic (non-branded) | 5mg once or twice a day (e.g. at breakfast and lunch), increasing if needed by weekly increments of 5 mg, up to a max of 20mg/daily in divided doses - although doses of 40 mg may in rare cases be needed. |
| Lisdexamfetamine  *Schedule 2 CD* | Elvanse®.  Note: Do not confuse with the “Elvanse Adult” brand | 30mg once daily (in the morning). The dose may be increased by 20mg increments, at approx. weekly intervals up to a max of 70mg once daily – but the lowest effective dose should be used. |
| Atomoxetine | Strattera® | For children/adolescents of up to 70kg body weight treatment should be initiated at 500 micrograms per kilogram daily and increased if necessary to a maximum of 1.8 mg/kg daily either in a single dose or divided doses.  For adolescents of over 70 kg body weight treatment should be initiated at a daily dose of 40 mg and increase according to response to a usual maintenance daily dose of 1.8 mg/kg. |

6. Adverse effects

Possible adverse effects and what to do if they occur:

|  |  |  |
| --- | --- | --- |
| **Adverse Effects include:** | **Frequency of adverse effect** | **GP Management** |
| **METHYLPHENIDATE** | | |
| Nervousness and insomnia | >10% | Review dose and/or omit afternoon/evening dose if using a three times daily dosing regime - refer to specialist for advice. |
| Decreased appetite | 1-10% | Usually transient. Try taking medicine with food if it persists. Refer to specialist for advice if continues |
| Headache, drowsiness, dizziness | 1-10% | Refer to specialist for advice if continues |
| Abdominal pain, diarrhoea, nausea & vomiting, dry mouth, dyspepsia | 1-10% | Occurs at initiation. May be alleviated by concomitant food intake. Refer to specialist for advice if continues |
| Tachycardia, arrhythmia, palpitations, hypertension | 1-10% | Monitor. Consider reducing or discontinuing the medication in light of clinical findings. Further investigations should be considered (including ECG, 24 hour BP and 24 hour ECG.  Consider referral to cardiology/ specialist physician. |
| Tic, aggression, anxiety, irritability | 1-10% | Consider discontinuing if tics develop. Refer back to specialist. |
| Drug induced psychosis,depression, mood swings | < 1% | Consider discontinuing. Refer back to specialist. |
| **DEXAMFETAMINE** | | |
| Aggressive behaviour, anxiety, confusion, delirium, depression, euphoria, insomnia, irritability, tics, night tremors | Not stated | Reduce dose & ensure not given too near bedtime. Consider discontinuing if tics develop. Refer back to specialist. |
| Paranoia, psychosis | Not stated | Consider discontinuing. Refer back to specialist. |
| Palpitations, tachycardia, change in blood pressure, cardiomyopathy, chest pain. | Not stated | Monitor. Check pulse after every dose change. ECG if necessary. Consider reducing or discontinuing the medication in light of clinical findings. Further investigations should be considered (including ECG, 24 hour BP and 24 hour ECG). Consider referral to cardiology/ specialist physician |
| **LISDEXAMFETAMINE** | | |
| Insomnia | >10% | Review dose - ensure taken in morning – refer to specialist for advise |
| Decreased appetite  (weight decreased) | >10%  (1-10%) | Try taking medicine with food if it persists. Refer to specialist for advice if continues |
| Headache, dry mouth | >10% | Refer to specialist for advice if continues |
| Anorexia, diarrhoea, upper abdominal pain, nausea | 1-10% | May be alleviated by concomitant food intake. Refer to specialist for advice if continues |
| Anxiety, agitation, dizziness, restlessness, tremor, irritability, fatigue, feeling jittery, hyperhidriosis | 1-10% | Refer back to specialist. |
| Tachycardia, palpitations, blood pressure increased  Cardiomyopathy, chest pain | 1-10%  Not stated | Monitor. Consider reducing or discontinuing the medication in light of clinical findings. Further investigations should be considered (including ECG, 24 hour BP and 24 hour ECG). Consider referral to cardiology/ specialist physician.  **See section 8 “Clinical Monitoring – Cardiovascular” for further information** |
| Depression, tic, affect lability, dysphoria, euphoria, mania, dermatillomania, somnolence, dyskineasia | 0.1-1% | Consider discontinuing if tics develop. Refer back to specialist. |
| Blurred vision, vomiting, urticaria, rash, pyrexia | 0.1-1% | Consider discontinuing. Refer back to specialist. |
| Psychotic episodes, hallucination, aggression, new or worsening seizures | Not known | Consider discontinuing. Refer back to specialist |
| **ATOMOXETINE** | | |
| Appetite decreased, dry mouth, nausea | >10% | Usually settles after 1st month of treatment. Refer to specialist for advice if continues |
| Headache, somnolence, insomnia | >10% | Usually settles after 1st month of treatment. Refer to specialist for advice if continues |
| Increased BP and heart rate | >10% | Monitor. Consider discontinuing if clinically indicated. Refer back to ADHD specialist and cardiologist if indicated. |
| Abdominal pain, constipation, dyspepsia, flatulence, vomiting | 1-10% | Usually settles after 1st month of treatment. Refer to specialist for advice if continues |
| Weight decrease | 1-10% | Usually settles after initial weight loss |
| Palpitations, tachycardia | 1-10% | Monitor. Consider discontinuing if clinically indicated. Refer back to ADHD specialist and cardiologist if indicated. |
| Sleep disorder, | 1-10% | Refer back to specialist |
| Libido decreased, sleep disorder, dizziness, sinus headache, tremor, fatigue, lethargy, agitation | 1-10% | Refer back to specialist |
| Dysuria, urinary hesitation, urinary retention | 1-10% | Refer back to specialist |
| Dysmenorrhoea, irregular menstruation, ejaculation disorder, erectile dysfunction, male genital pain | 1-10% | Refer back to specialist |
| QT interval prolongation, | 0.1-1% | Monitor. Consider reducing or discontinuing the medication in light of clinical findings. Further investigations should be considered (including ECG, 24 hour BP and 24 hour ECG). Consider referral to cardiology/ specialist physician |
| Hepatic disorders | Rare | The CSM has advised that patients and carers should be informed of the risk and be told how to recognise symptoms; prompt medical attention should be sought in case of abdominal pain, unexplained nausea and malaise, darkening of the urine or jaundice.  Consider discontinuing. Refer back to specialist. |
| Suicide-related events, aggression, hostility and emotional lability. | 0.1-1% | Following reports of suicidal thoughts and behaviour, the CSM has advised that patients and their carers should be informed about the risk and told to report clinical worsening, suicidal thoughts or behaviour, irritability, agitation, or depression.  Consider discontinuing. Refer back to specialist. |

Suspected adverse drug reactions should be reported to the MHRA using the Yellow Card Scheme at [www.yellowcard.mhra.gov.uk](file:///C:\Users\jane.moriba\AppData\Local\Microsoft\Windows\Temporary%20Internet%20Files\Content.Outlook\9QTZG6KF\www.yellowcard.mhra.gov.uk). Refer to BNF for further details.

For a full list of adverse effects , refer to the Summary of Product Characteristics ([www.medicines.org.uk](http://www.medicines.org.uk)) .

1. Cautions

**Methylphenidate:** Co-existing cardiac disease or psychiatric disorder, anxiety/agitation/tension, tics or family history of Tourette or other movement disorders, risk of dependence/diversion/misuse of medication (both prior to initiation and ongoing during treatment), epilepsy, pregnancy, breast feeding; avoid abrupt withdrawal.

**Dexamfetamine / Lisdexamfetamine:** Anorexia, mild hypertension, psychosis or bipolar disorder, renal impairment, history of epilepsy, tics or Tourette syndrome, risk of dependence/diversion/misuse of medication (both prior to initiation and ongoing during treatment), avoid abrupt withdrawal.

**Atomoxetine**: Cardiovascular disease, structural cardiac abnormalities, QT interval prolongation, psychosis/mania, history of seizures, aggressive behaviour/hostility/emotional lability, hepatic impairment.

For a full list of cautions, refer to the Summary of Product Characteristics ([www.medicines.org.uk](http://www.medicines.org.uk)).

1. Clinical Monitoring

Once prescribing is undertaken by the GP, some or all of the necessary clinical monitoring will take place in Primary Care. This is dependent on the facilities of the specialist clinic and the patients geographical location. The Specialist will advise the GP on the clinical monitoring requirements (including test and frequency) that is required. The ADHD service will offer specialist advice and review any patient whose medication was started in the clinic at the request of the GP.

Patients will need to be re-referred to the service if they have already been discharged from the Specialist team (e.g. CAMHS).

If there is a need for specialist advice / interventions for patients who have an ADHD diagnosis / treatment, which was established elsewhere, a new referral to the service will be needed.

The following tests may be suggested by the ADHD service to monitor in Primary care. If suitable, a practice nurse may be able to complete these tests and escalate to the GP if there is cause for concern.

**Height and weight**:

* Measure height every 6 months in children and young people
* Measure weight every 3 months in children **10 years and under.** Measureat 3 and 6 months after starting treatment in children **over 10 years and young people**, and every 6 months thereafter, or more often if concerns arise.
* Record height and weight of children and young people and plot on a growth chart (in lieu of a growth chart, in the patient notes record the difference in growth centiles from the previous measurements/readings).
* Consultants in NCL may decide that physical observations may only be necessary once every six months (if the patient has been stable on therapy for a significant amount of time and physical observations have also been stable). The Consultant should communicate this to the GP on every occasion.
* If a trend of weight loss or growth retardation is observed in results over time, seek advice from a psychiatrist or paediatrician from the initiating clinic to consider stopping the medicine as an interim measure; in all instances the patient should be referred back to clinic.

**Cardiovascular:**

* Monitor heart rate and blood pressure and compare with the normal range for age, before and after each dose change and every 6 months.
* Routine blood tests (including liver function tests) or ECGs should not be done unless there is a clinical indication. Those patients who require routine blood tests or ECGs will be highlighted by the Consultant when prescribing responsibility is transferred to the GP.

**Management of adverse effects:**

* If patient has a sustained resting tachycardia (more than 120 beats per minute), arrhythmia or systolic blood pressure greater than the 95th percentile (or a clinically significant increase) measured on 2 occasions, reduce their dose and refer them to a paediatric hypertension specialist or adult physician, as appropriate.
* For other severe adverse effects (e.g. new or worsening seizures, new emerging psychotic symptoms), it is recommended to stop the patient’s treatment and refer the patient back into the initiating clinic.
* For other mild/moderate adverse effects (e.g. dyspepsia), consider reducing the dose or stopping the medication and refer the patient back into the initiating clinic.

**Risk of diversion**

* Healthcare professionals and parents or carers should monitor changes in the potential for stimulant misuse and diversion, which may come with changes in circumstances and age.

1. Contraindications

* **Atomoxetine**: Concomitant use or use within 2 weeks of MAOI, narrow-angle glaucoma, severe cardiovascular or cerebrovascular disorders, pheochromocytoma.
* **Dexamfetamine/Lisdexamfetamine:** Symptomatic cardiovascular disease, structural cardiac abnormalities, moderate or severe hypertension, advanced arteriosclerosis, concomitant use or use within 2 weeks of MAOI, history of drug/alcohol abuse, hyperthyroidism, glaucoma, agitated states, severe depression, anorexia nervosa/anorexic disorders, suicidal ideation, hyper-excitability, psychotic symptoms, severe and episodic (Type I) Bipolar (affective) Disorder (that is not well-controlled.
* **Methylphenidate:** Severe depression, suicidal ideation, psychosis, anorexia nervosa, cardiovascular disease, severe hypertension, hyperthyroidism, glaucoma, concomitant use or use within 2 weeks of MAOI
* For a full list of contraindications, refer to the Summary of Product Characteristics [www.medicines.org.uk](http://www.medicines.org.uk).

1. Drug Interactions

**Atomoxetine:**

* **Antidepressants**- Risk of hypertensive crisis when given with MAOI/moclobemide. Metabolism of atomoxetine possibly inhibited by fluoxetine and paroxetine. Increased risk of convulsions with atomoxetine and antidepressants (including bupropion).
* **Analgesics**- Increased risk of ventricular arrhythmias with concomitant use of atomoxetine and methadone. Possible increased risk of convulsions with concomitant use with tramadol.
* **Coumarin anticoagulants e.g. warfarin** - Increased anticoagulant effects CYP2D6 inhibitor drugs e.g. fluoxetine (SSRIs), increased serum levels and drowsiness tricyclic antidepressants. Increased serum levels and side effects.
* Increased risk of cardiovascular side effects when given with **beta2 agonists** (high dose) e.g. high dose salbutamol. Increased agonist effects.

**Dexamfetamine/ Lisdexamfetamine:**

* **Antidepressants**- Risk of hypertensive crisis when given with MAOI/moclobemide.
* **Antipsychotics**- Lis/Dexamfetamine possibly antagonises antipsychotic effects of chlorpromazine, methylphenidate possibly increases side effects of risperidone. Increased risk of ventricular arrhythmias when atomoxetine given with antipsychotics that prolong QT interval
* Avoid concomitant use of **MAO Inhibitors**. Risk of Hypertensive crisis. Avoid lisdexamfetamine at least for 2 weeks after stopping MAOI.
* **Antihypertensive**: lisdexamfetamine may reduce the antihypertensive effect of guanethidine and others.
* Increased analgesic effects of **morphine and other opioids**.

**Methylphenidate:**

* **Antidepressants**- Risk of hypertensive crisis when given with MAOI/moclobemide. methylphenidate possibly inhibits metabolism of SSRI’s and TCA’s.
* May inhibit the metabolism of **coumarin anticoagulants**, some **anticonvulsants** (phenobarbitones, phenytoin and primidone), phenylbutazone and tricyclic antidepressants. The dosage of these drugs may have to be reduced.
* Use in caution with **MAOI.**
* **Alcohol** may exacerbate the adverse CNS effect of methylphenidate. Patients should be advised to abstain from alcohol during treatment.
* **Pseudoephedrine, phenylpropanolamine** (both found in OTC cough remedies). Patients should be warned when buying cough medicines.
* Methylphenidate can worsen the side effects of **risperidone**.

For a more detailed list of drug interactions, refer to the manufacturer’s Summary of Product Characteristics (SPC) (on [www.medicines.org.uk](http://www.medicines.org.uk) or <https://products.mhra.gov.uk/>) and current children’s BNF (<https://bnfc.nice.org.uk/>).

1. References

* NICE Guideline 87; Attention deficit hyperactivity disorder: diagnosis and management (September 2019) <https://www.nice.org.uk/guidance/ng87>
* Summary of Product Characteristics <http://www.medicines.org.uk>
* BNF online <https://bnf.nice.org.uk/>
* Shared Care ADHD in Adults Barnet Enfield and Haringey February 2010 (template and original information).
* NCL Shared Care Guideline Methylphenidate (immediate release and long acting), Lisdexamfetamine, Atomoxetine and Dexamfetamine for treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD), March 2019.
* Barnet, Enfield and Haringey Mental Health Trust shared care guidelines for methylphenidate, dexamfetamine and atomoxetine for ADHD in Children 2015.
* Attention defificit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate Evidence summary: new medicine Published: May 2013.nice.org.uk/guidance/esnm19. <https://www.nice.org.uk/advice/esnm19/resources/attention-deficit-hyperactivity-disorder-in-children-and-young-people-lisdexamfetamine-dimesylate-pdf-1502680811289541>
* Jadad AR, Boyle M, Cunningham C et al. Treatment of attention deficit hyperactivity disorder, Evid Rep Technol Assess (Summ) 1999 Nov:1-341. http:/www.ahcpr.gov (In Evidence Based Medicine, Issue No 7. June 2002)
* NIH Consensus Statement: Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder (ADHD): National Institutes of Health 15:2; Nov 1998

1. Contact Details

|  |  |
| --- | --- |
| **HOSPITAL SWITCHBOARD:** | **020 8702 3000** |
| **BARNET SERVICE**  Holly -Oak (Dennis Scott Unit)  Edgware Community Hospital  Burnt Oak Broadway  Edgware  HA8 0AD | **Tel: 020 8702 4500/ 3444/ 3300**  [**beh-tr.camhsadmin@nhs.net**](mailto:beh-tr.camhsadmin@nhs.net) |
| **ENFIELD SERVICE**:  Bay Tree House  Church Close  Enfield , Middlesex  EN2 6NZ | **Tel: 020 8702 4070 (S.A.F.E) or 020 8702 5100 (Generic CAMHS Team)**  [**beh-tr.enfieldcamhs@nhs.net**](mailto:beh-tr.enfieldcamhs@nhs.net) |
| **HARINGEY SERVICE:**  St Ann’s Hospital – H Block  St Ann’s Road  Tottenham  London  N15 3TH | **Tel: 020 8702 5154 or 020 8702 3400**  [**beh-tr.camhsreferral@nhs.net**](mailto:beh-tr.camhsreferral@nhs.net) |
| **ISLINGTON SERVICE:**  **Islington Child and Adolescent Mental Health Service (CAMHS)**  Whittington Health NHS Trust  Magdala Avenue  London  N19 5NF | **Tel: 020 7272 3070**  [**whh-tr.icamhsadmin@nhs.net**](mailto:whh-tr.icamhsadmin@nhs.net) |
| **South Camden Community Team**  Openminded  219 Eversholt Street,  London  NW1 1DR | **Tel: 020 8938 2700**  **Each team has their own admin address; if the initiating Specialist cannot be contacted, please contact the central referral email who can re-direct your enquiry:** [**tpn-tr.CYAF-Intake@nhs.net**](mailto:tpn-tr.CYAF-Intake@nhs.net) |
| **Children and young people's psychological services**  University College London Hospital  Elizabeth Garrett Anderson Wing  Lower Ground Floor  235 Euston Road  London, NW1 2BU | **Tel: 020 3447 9086**  **The email address for patient enquiries can be found at** [**https://www.uclh.nhs.uk/OurServices/ServiceA-Z/CYPS/CAPS/Pages/Home.aspx**](https://www.uclh.nhs.uk/OurServices/ServiceA-Z/CYPS/CAPS/Pages/Home.aspx) |
| **Camden MOSAIC**  Kentish Town Health Centre  Bartholomew Road  London  NW5 2AJ | **Tel: 020 3317 2200 or 020 8938 2241**  **Each team has their own admin address; if the initiating Specialist cannot be contacted, please contact the central referral email who can re-direct your enquiry:** [**tpn-tr.CYAF-Intake@nhs.net**](mailto:tpn-tr.CYAF-Intake@nhs.net) |

**Document control**

|  |  |  |
| --- | --- | --- |
| Date | Version | Amendments |
| June 2020 | V1.0 | New document  (based on previous BEHMHT November 2015). |

|  |  |
| --- | --- |
| Groups / Individuals who have overseen the development of this guidance: | Dr Raj Sekaran (Consultant, BEH)  Jane Moriba (Senior Pharmacist, BEH)  Gurpal Grewal (Support Pharmacist, JFC) |
| Groups which were consulted and have given approval: | NCL Trust Formulary Pharmacists and CCG HoMM  BEH MHT Drugs and Therapeutics Committee  NCL Shared Care Group  NCL Child & Adolescent Psychiatrists and Paediatricians |
| File name: | NCL children and adolescent ADHD Shared Care |
| Version number: | 1.0 |
| Available on: | [www.ncl-mon.nhs.uk](http://www.ncl-mon.nhs.uk) |
| Disseminated to: | Formulary Pharmacists, Commissioners and CAMHS services |
| Equality impact assessment: | Nil identified |
| NCL Shared Care Group Approval date: | June 2020 |
| Review date: | June 2023 |

Appendix 1: Transfer form to GP practice

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Section A: to be completed by secondary care** *Send to practice*  *This document is to request the shared care pathway of your patient and comprises an agreement between the GP and named Consultant. The patient will continue to be seen by the named Consultant as regular follow up.* | | | | | | | | | |
| *Fix address label here (ensure NHS no. is on label)* | | | | |  | Clinic stamp *or give details below* | | | |
|  |
|  |
|  | | | | | | | | | |
| Department |  | | | |  |  | | | |
|  | | | | | |  | | | |
|  | | | | | |  | | | |
| Consultant |  | | | |  | Email |  | | |
|  | | | | | | | | | |
| Indication for prescription |  | | | | | | | | |
|  | | | | | | | | | |
| Drug prescribed |  | | | | | | | | |
|  | | | | | | | | | |
| Date Drug started | |  | | Current dose | | | |  |  |
|  | | | | | | | | | |
| Relevant conditions |  | | | | | | | | |
|  | | | | | | | | | |
| Monitoring variations |  | | | | | | | | |
|  | | | | | | | | | |
| Date next blood test |  | | Next disease review due in | | | | |  | months’ time. |
|  | | | | | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Section B: [Accept Shared Care] to be completed by practice** *Send back* ***FAO referring Consultant*** *above*  The above patient has been accepted into our monitoring service. | | | | |
| Practice date for next blood test | |  |  | Practice stamp or add details below |
|  | | |  |
| Signed /  Designation |  | |  |
| Date | | |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Section B: [Reject Shared Care] to be completed by practice** *Send back* ***FAO referring Consultant*** *above*  The above patient has not been accepted into our monitoring service. | | | | |
| Reason | |  |  | Practice stamp or add details below |
|  | | |  |
| Signed /  Designation |  | |  |
| Date | | |  |

**Section C: Shared Care Agreement (Trust specific information)**

*This section (and reference to it: Consultant Shared Care Responsibilities point 3) can be removed if all Trusts and CCGs have the same contractual arrangements.*

|  |  |
| --- | --- |
| **Contact details** | |
| Clinic / service |  |
| Address |  |
| Email |  |
| Telephone |  |

**Contractual details**

|  |  |
| --- | --- |
| CCG 1 |  |
| No. weeks Trust to prescribe |  |
| Treatment reviews to be conducted by trust (frequency) |  |

|  |  |
| --- | --- |
| CCG 2 |  |
| No. weeks Trust to prescribe |  |
| Treatment reviews to be conducted by trust (frequency) |  |

|  |  |
| --- | --- |
| CCG 3 |  |
| No. weeks Trust to prescribe |  |
| Treatment reviews to be conducted by trust (frequency) |  |